Valneva SE
PAR:VLA

Watchlist Manager
Valneva SE Logo
Valneva SE
PAR:VLA
Watchlist
Price: 2.036 EUR -0.2% Market Closed
Market Cap: 330.6m EUR
Have any thoughts about
Valneva SE?
Write Note

Intrinsic Value

VLA's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one VLA stock under the Base Case scenario is 6.24 EUR. Compared to the current market price of 2.036 EUR, Valneva SE is Undervalued by 67%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

VLA Intrinsic Value
6.24 EUR
Undervaluation 67%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Valneva SE

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for VLA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about VLA?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Valneva SE

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Valneva SE

Provide an overview of the primary business activities
of Valneva SE.

What unique competitive advantages
does Valneva SE hold over its rivals?

What risks and challenges
does Valneva SE face in the near future?

Has there been any significant insider trading activity
in Valneva SE recently?

Summarize the latest earnings call
of Valneva SE.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Valneva SE.

Provide P/S
for Valneva SE.

Provide P/E
for Valneva SE.

Provide P/OCF
for Valneva SE.

Provide P/FCFE
for Valneva SE.

Provide P/B
for Valneva SE.

Provide EV/S
for Valneva SE.

Provide EV/GP
for Valneva SE.

Provide EV/EBITDA
for Valneva SE.

Provide EV/EBIT
for Valneva SE.

Provide EV/OCF
for Valneva SE.

Provide EV/FCFF
for Valneva SE.

Provide EV/IC
for Valneva SE.

Show me price targets
for Valneva SE made by professional analysts.

What are the Revenue projections
for Valneva SE?

How accurate were the past Revenue estimates
for Valneva SE?

What are the Net Income projections
for Valneva SE?

How accurate were the past Net Income estimates
for Valneva SE?

What are the EPS projections
for Valneva SE?

How accurate were the past EPS estimates
for Valneva SE?

What are the EBIT projections
for Valneva SE?

How accurate were the past EBIT estimates
for Valneva SE?

Compare the revenue forecasts
for Valneva SE with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Valneva SE and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Valneva SE against its competitors.

Analyze the profit margins
(gross, operating, and net) of Valneva SE compared to its peers.

Compare the P/E ratios
of Valneva SE against its peers.

Discuss the investment returns and shareholder value creation
comparing Valneva SE with its peers.

Analyze the financial leverage
of Valneva SE compared to its main competitors.

Show all profitability ratios
for Valneva SE.

Provide ROE
for Valneva SE.

Provide ROA
for Valneva SE.

Provide ROIC
for Valneva SE.

Provide ROCE
for Valneva SE.

Provide Gross Margin
for Valneva SE.

Provide Operating Margin
for Valneva SE.

Provide Net Margin
for Valneva SE.

Provide FCF Margin
for Valneva SE.

Show all solvency ratios
for Valneva SE.

Provide D/E Ratio
for Valneva SE.

Provide D/A Ratio
for Valneva SE.

Provide Interest Coverage Ratio
for Valneva SE.

Provide Altman Z-Score Ratio
for Valneva SE.

Provide Quick Ratio
for Valneva SE.

Provide Current Ratio
for Valneva SE.

Provide Cash Ratio
for Valneva SE.

What is the historical Revenue growth
over the last 5 years for Valneva SE?

What is the historical Net Income growth
over the last 5 years for Valneva SE?

What is the current Free Cash Flow
of Valneva SE?

Discuss the annual earnings per share (EPS)
trend over the past five years for Valneva SE.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Valneva SE

Current Assets 269.2m
Cash & Short-Term Investments 131.4m
Receivables 30.5m
Other Current Assets 107.2m
Non-Current Assets 197.4m
PP&E 156.5m
Intangibles 24.2m
Other Non-Current Assets 16.7m
Current Liabilities 102.5m
Accounts Payable 8.5m
Accrued Liabilities 41.5m
Other Current Liabilities 52.5m
Non-Current Liabilities 197.8m
Long-Term Debt 187.1m
Other Non-Current Liabilities 10.7m
Efficiency

Earnings Waterfall
Valneva SE

Revenue
229.4m EUR
Cost of Revenue
-140.5m EUR
Gross Profit
88.9m EUR
Operating Expenses
-33.6m EUR
Operating Income
55.3m EUR
Other Expenses
-38m EUR
Net Income
17.3m EUR

Free Cash Flow Analysis
Valneva SE

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Valneva showcased robust Q1 2024 results, achieving a net profit nearing €60 million and maintaining €175 million in cash. Product sales remained steady at €32.1 million, aligning with internal forecasts. Significant pipeline advancements include the chikungunya vaccine, now generating initial revenues following favorable CDC recommendations. The Phase III Lyme disease study progresses on schedule, and the Zika vaccine advances into Phase I. The company reaffirmed its 2024 guidance of €160-180 million in product sales and expects sustained profitability from 2025, excluding Lyme-related revenues, which are anticipated in early 2027.

What is Earnings Call?
Fundamental Scores

VLA Profitability Score
Profitability Due Diligence

Valneva SE's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

ROE is Increasing
ROIC is Increasing
Positive Gross Profit
Exceptional Revenue Growth Forecast
33/100
Profitability
Score

Valneva SE's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

VLA Solvency Score
Solvency Due Diligence

Valneva SE's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Positive Net Debt
Average D/E
38/100
Solvency
Score

Valneva SE's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VLA Price Targets Summary
Valneva SE

Wall Street analysts forecast VLA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VLA is 7.758 EUR with a low forecast of 2.879 EUR and a high forecast of 11.55 EUR.

Lowest
Price Target
2.879 EUR
41% Upside
Average
Price Target
7.758 EUR
281% Upside
Highest
Price Target
11.55 EUR
467% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for VLA?

Click here to dive deeper.

Dividends

Valneva SE
does not pay dividends
Shareholder Yield

Current shareholder yield for VLA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

VLA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

VLA News

Profile

Valneva SE Logo
Valneva SE

Country

France

Industry

Biotechnology

Market Cap

330.6m EUR

Dividend Yield

0%

Description

Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Contact

PAYS DE LA LOIRE
Saint-Herblain
6 rue Alain Bombard
+33228073710.0
valneva.com

IPO

2007-06-28

Employees

722

Officers

President, CEO & Director
Mr. Thomas Lingelbach
Chief Financial Officer
Mr. Peter Buhler
VP of Legal & IP, General Counsel, and Corporate Secretary
Mr. Frederic Jacotot
Chief Business Officer
Mr. Franck Grimaud MBA
Chief Medical Officer
Dr. Juan-Carlos Jaramillo M.D.
Chief Commercial Officer
Ms. Dipal Patel
Show More
Chief Operating Officer
Mr. Vincent Dequenne
Chief Scientific Officer
Dr. Hanneke Schuitemaker Ph.D.
Vice President of Investor Relations
Mr. Joshua Drumm Ph.D.
VP of Global Communications & European Investor Relations
Ms. Laetitia Bachelot-Fontaine
Show Less

See Also

Discover More
What is the Intrinsic Value of one VLA stock?

The intrinsic value of one VLA stock under the Base Case scenario is 6.24 EUR.

Is VLA stock undervalued or overvalued?

Compared to the current market price of 2.036 EUR, Valneva SE is Undervalued by 67%.

Back to Top